NTRA - Natera, Inc.
26.15 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 26.18 |
| Open | 26.26 |
| Bid | 26.11 x 800 |
| Ask | 26.13 x 900 |
| Day's Range | 25.71 - 26.26 |
| 52 Week Range | 11.08 - 29.62 |
| Volume | 222,078 |
| Avg. Volume | 692,220 |
| Market Cap | 1.82B |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.15 |
| Earnings Date | Mar 11, 2019 - Mar 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.67 |
- Simply Wall St.•yesterday
Is Natera's (NASDAQ:NTRA) Share Price Gain Of 104% Well Earned?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Motley Fool•11 days ago
Here's Why Natera Stock Soared 97.6% in the First Half of 2019
Investors are excited about two new products for the genetic testing and liquid biopsy developer.
- PR Newswire•29 days ago
New ProActive™ Study From Natera Will Test for Rejection in 3,000 Kidney Transplant Recipients
SAN CARLOS, Calif., June 24, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced a nationwide registry study for kidney transplant recipients called ProActive. This is one of the largest known prospective studies to date, incorporating donor-derived cell-free DNA (dd-cfDNA) testing into medical management of organ transplant recipients. The ProActive study will prospectively enroll 3,000 kidney transplant patients from the time of surgery, and will measure changes in biopsy usage and clinical outcomes based on physician-directed use of the Prospera test to rule-in and rule-out active rejection.
- Zacks•last month
46 and You: Genetic Testing = Giant Growth Market
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
- Insider Monkey•last month
Did Hedge Funds Drop The Ball On Natera Inc (NTRA) ?
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Zacks•last month
Natera, Inc.'s Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Natera.
- Thomson Reuters StreetEvents•last month
Edited Transcript of NTRA earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Natera Inc Earnings Call
- Simply Wall St.•2 months ago
What Kind Of Shareholder Owns Most Natera, Inc. (NASDAQ:NTRA) Stock?
A look at the shareholders of Natera, Inc. (NASDAQ:NTRA) can tell us which group is most powerful. Generally speaking...
- PR Newswire•2 months ago
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness SAN CARLOS, Calif. , June 3, 2019 /PRNewswire/ -- A new study demonstrates ...
- Zacks•2 months ago
Natera, Inc. (NTRA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Natera, Inc. (NTRA).
- PR Newswire•2 months ago
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test
Represents Major Commercialization Milestone SAN CARLOS, Calif. , May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California -based laboratories, has posted a favorable ...
- Zacks•2 months ago
OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%
OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Motley Fool•2 months agoNatera (NTRA) Q1 2019 Earnings Call Transcript
NTRA earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 8.47% and 0.63%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Natera: 1Q Earnings Snapshot
On a per-share basis, the San Carlos, California-based company said it had a loss of 54 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•2 months ago
Natera Reports First Quarter 2019 Financial Results
SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for ...
- PR Newswire•2 months ago
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
JAMA Oncology Study Suggests Potential for Natera's Signatera Test to Guide Treatment Decisions After Surgery SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ ...
- PR Newswire•3 months ago
Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards
Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection SAN CARLOS, Calif. , May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced ...
- PR Newswire•3 months ago
FDA Grants Breakthrough Device Designation to Natera's Signatera Test
Accelerated Regulatory Review Intended to Expedite Use of Test in Pharmaceutical Trials and Improve Upon Current Clinical Standards SAN CARLOS, Calif. , May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: ...
- Insider Monkey•3 months ago
Did Hedge Funds Drop The Ball On Natera Inc (NTRA)?
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- PR Newswire•3 months ago
Natera Announces First Quarter 2019 Earnings Conference Call
SAN CARLOS, Calif. , May 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release ...
- PR Newswire•3 months ago
Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 ...
- Benzinga•3 months ago
The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...
- PR Newswire•3 months ago
Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 ...
- PR Newswire•3 months ago
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signatera™ research-use-only (RUO) molecular residual disease (MRD) assay detected disease relapse up to two years earlier than imaging in patients with early-stage breast cancer.1 The new publication validates clinical performance of Signatera for recurrence monitoring and MRD assessment in breast cancer. The results were published online today in the latest issue of Clinical Cancer Research.
